India’s vaccination drive picks up for adults but long road ahead for children
Covaxin phase 2/3 studies have been completed for 2 to 17 years age group population and immunogenicity and safety data have been submitted to the Drugs Controller General of India (DCGI) for further approvals. Even as India’s cumulative Covid-19 vaccination coverage exceeds 75.89 Crore, Covid-19 vaccination of children with comorbidities in the 12 to 17 … Read more